Thyrogen

Thyrogen is a brand name of thyrotropin alpha, approved by the FDA in the following formulation(s):

THYROGEN (thyrotropin alfa - injectable; injection)

• 
  Manufacturer: GENZYME
  
  Approval date: November 30, 1998
  
  Strength(s): 1.1MG/VIAL ^[RLD]

Has a generic version of Thyrogen been approved?

No. There is currently no therapeutically equivalent version of Thyrogen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Thyrogen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Isolation of a gene encoding human thyrotropin beta subunit
  Patent 5,840,566
  Issued: November 24, 1998
  Inventor(s): Kourides; Ione A. & Whitfield; Graham Kerr
  Assignee(s): Sloan-Kettering Institute for Cancer Research
  The gene expressing the beta subunit of human thyroid stimulating hormone has been isolated. The gene has been incorporated into plasmid pBR322. Vectors can be used to transform cells which in turn produce pure beta subunits. The beta subunits can then be combined with the alpha subunit of human glycoprotein hormones to produce pure thyroid stimulating hormone.
  
  Patent expiration dates:
  
  
  • November 24, 2015
    
  
  



• 
  Isolation of a gene encoding human thyrotropin beta subunit
  Patent 6,365,127
  Issued: April 2, 2002
  Inventor(s): Ione A.; Kourides & Graham Kerr; Whitfield
  Assignee(s): Sloan-Kettering Institute for Cancer Research
  The gene expressing the beta subunit of human thyroid stimulating hormone has been isolated. The gene has been incorporated into plasmid pBR322. Vectors can be used to transform cells which in turn produce pure beta subunits. The beta subunits can then be combined with the alpha subunit of human glycoprotein hormones to produce pure thyroid stimulating hormone.
  
  Patent expiration dates:
  
  
  • November 24, 2015
    
    ✓ 
    Patent use: USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 14, 2010 - ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
  
  
  • December 14, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Thyrogen Consumer Information (Wolters Kluwer)
• Thyrogen Advanced Consumer Information (Micromedex)
• Thyrotropin Alfa Consumer Information (Wolters Kluwer)
• Thytropar Advanced Consumer Information (Micromedex)
• Thyrotropin Injection Advanced Consumer Information (Micromedex)